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Abstract: 29 
 30 
Chemotherapeutics represent the main approach for the treatment of leukemia. However, the 31 
occurrence of adverse side effects and the complete lack of effectiveness in some cases make it 32 
necessary to develop new drugs. As part of our screening program to evaluate the potential 33 
chemotherapeutic effect of natural coumarins, we investigated the anti-leukemic activities of a 34 
series of six prenylated coumarins isolated from the stem bark of Toddalia asiatica (Rutaceae). 35 
Among these, 6-(3-methyl-2-butenyl)-5,7-dimethoxycoumarin (toddaculin) displayed the most potent 36 
cytotoxic and anti-proliferative effects in U-937 cells. To determine whether these effects resulted 37 
from induction of cell death or differentiation, we further evaluated the expression of several 38 
apoptosis and maturation markers. Interestingly, while toddaculin at 250 µM was able to induce 39 
apoptosis in U-937 cells, involving decreased phosphorylation levels of ERK and Akt, 50 µM 40 
toddaculin exerted differentiating effects, inducing both the capacity of U-937 cells to reduce NBT 41 
and the expression of differentiation markers CD88 and CD11b, but no change in p-Akt or p-ERK 42 
levels. Taken together, these findings indicate that toddaculin displays a dual effect as a cell 43 
differentiating agent and apoptosis inducer in U-937 cells, suggesting it may serve as a 44 
pharmacological prototype for the development of novel anti-leukemic agents. 45 
 46 
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Abbreviations: 60 
ATP: adenosine triphosphate. ATRA: all-trans-retinoic acid. CC50: cytotoxic concentration 50. db-61 
cAMP: dibutyryl cyclic adenosine monophosphate. DMSO: dimethyl sulfoxide. EIMS: electron 62 
impact mass spectrometry. ERK: extracellular signal-regulated protein kinase. FCS: fetal calf 63 
serum. FITC: fluorescein isothiocyanate. HO: Hoechst 33342. IC50: inhibitory proliferation 64 
concentration 50. JNK: c-Jun N-terminal kinase. MAPK: mitogen-activated protein kinase. NBT: 65 
nitroblue tetrazolium. NMR: nuclear magnetic resonance. PARP: Poly-(ADP-ribose)-polymerase. 66 
PBS: phosphate-buffered saline. PI: Propidium iodide. rhC5a: recombinant human complement 67 
factor C5a.  68 
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Introduction 85 
 86 
Natural products, such as plant extracts and microbial compounds, have achieved high 87 
prominence in the development of commercial drugs. In this regard, approximately 74% of the 88 
chemotherapeutics currently employed in the treatment of cancer are either natural products or 89 
natural product-derived drugs (Tan, 2006). Occurring widely throughout the Plant Kingdom, 90 
coumarins (known as 1,2-benzopyrones) constitute one of the most representative families of plant 91 
secondary metabolites, displaying a broad spectrum of biological activities. These include anti-92 
bacterial (Laurin, 1999), oral anti-coagulant (Olderburg, 2007), anti-mutagenic (Pillai, 1999) and 93 
anti-inflammatory properties (Fylaktakidou, 2004), as well as capacity to inhibit human platelet 94 
aggregation (Roma, 2003), reactive oxygen species scavenging capacity (Kancheva, 2010) and 95 
anti-HIV activity (Kirkiacharian, 2002).  96 
Our group and others have identified novel coumarin compounds with anti-proliferative and/or 97 
cytotoxic activity on cancer cells, depending on their substitution pattern (Riveiro, 2010). 98 
Specifically, in previous publications, we reported the significant inhibitory activity of certain 99 
coumarins on the proliferation of leukemic cell lines (Riveiro, 2004, 2008a, b and 2009). In addition, 100 
we described that such inhibitory effects could be related to either differentiating (Riveiro, 2004, 101 
2009) or pro-apoptotic activities (Riveiro, 2008a, b) of the compounds, depending on the distribution 102 
of their substituents in the coumarin ring. 103 
Toddalia asiatica (Rutaceae) is a woody liana widely distributed in Southeast Asia, South Africa 104 
and tropical Africa, including Madagascar. The genus Toddalia is known to produce prenylated 105 
coumarins and phenanthridine alkaloids and derivatives. Of interest, the antineoplastic activity of an 106 
alkaloid extracted from T. asiatica has been described previously (Iwasaki, 2006 and 2010), but 107 
there is no published report on the anti-cancer activity of prenylated coumarins. Thus, aiming to 108 
extend our previous research, in the present work we performed a screening of six natural 109 
prenylated coumarins isolated from Toddalia asiatica for potential effects on U-937 cell proliferation, 110 
viability and differentiation, as well as for pro-apoptotic activity. Table 1 shows the structures of 111 
these coumarins (compounds 1 – 6).  112 
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Among the evaluated compounds, the 6-(3-methyl-2-butenyl)-5,7-dimethoxycoumarin, 113 
toddaculin (6) was the most potent in terms of anti-proliferative and cytotoxic activities. What is 114 
more, this coumarin was able to promote apoptosis and partial differentiation in a concentration- 115 
and time-dependent manner. In this regard, at higher concentrations toddaculin (6) induced U-937 116 
cell death mediated by caspase cascade activation and down-regulation of ERK 1/2 and 117 
serine/threonine protein kinase Akt phosphorylation, whereas at lower concentrations it induced 118 
NBT reduction and expression of CD11b and CD88 monocytic differentiation markers. 119 
Collectively, the findings presented herein constitute the first report to demonstrate the pro-120 
apoptotic and differentiating activities of the natural coumarin toddaculin (6) on U-937 cells, 121 
pharmacological properties that may be useful for the development of novel chemotherapeutic 122 
agents for the treatment of leukemia. 123 
 124 
 125 
Materials and Methods 126 
 127 
Reagents and antibodies 128 
 129 
RPMI 1640 medium, gentamicin antibiotic, bovine serum albumin, db-cAMP, PBS, Fura 2-AM, 130 
rhC5a, RNase A, ATP, HO, PI, NBT and PMA were obtained from Sigma Chemical Co. (St. Louis, 131 
USA). DMSO was obtained from Baker (Deventer, The Netherlands). FCS was purchased from 132 
PAA Laboratories GmbH (Austria). Anti-caspase-3, anti-PARP, anti-p-Akt, anti-Akt, anti-p-ERK 1/2, 133 
anti-ERK 1/2, anti-p-JNK, anti-JNK, anti-p-p38, anti-p38, anti-rabbit and anti-mouse-HRP IgG 134 
antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, USA). All commercial 135 
chemicals and solvents were of reagent grade and used without further purification unless 136 
otherwise specified. 137 
 138 
 139 
 140 
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Compounds 141 
 142 
Toddalia asiatica (Rutaceae) was collected in the Blyde Nature Reserve, Mpumalanga, South 143 
Africa, and a voucher specimen retained (N. Crouch & O. Grace 991, NH).  The combined dried and 144 
milled stem wood and bark were extracted sequentially with hexane, dichloromethane, ethyl acetate 145 
and methanol using a Soxhlet apparatus. Repeated column chromatography over silica gel (Merck 146 
9385) and solvent systems yielded the six prenylated coumarins shown in Table 1: 6-(2,3-epoxy-3-147 
methylbutyl)-5,7-dimethoxycoumarin (aeculeatin, 1); 6-(3-methyl-2-butenyloxy)-5,7-148 
dimethoxycoumarin (2); 8-(3-methyl-2-butenyl)-6,7-dimethoxycoumarin (O-methylcedrelopsin, 3); 6-149 
(2-hydroxy-3-methyl-3-butenyl)-5,7-dimethoxycoumarin (toddanol, 4); 6-(2,3-dihydroxy-3-150 
methylbutyl)-5,7-dimethoxycoumarin (toddalolactone, 5) and 6-(3-methyl-2-butenyl)-5,7-151 
dimethoxycoumarin (toddaculin, 6).  152 
The structures of these compounds were determined using 2D NMR and EIMS techniques, and 153 
confirmed by comparison of spectroscopic data for the compounds isolated against literature data 154 
(Sharma, 1981). 155 
The coumarin 5,7-dimethoxy-4-methylcoumarin (7; Table 1) was obtained from INDOFINE 156 
Chemical Company, Inc. (Boston, USA).  157 
Both commercial and natural coumarins listed on Table 1 were dissolved in DMSO and stored at 158 
-20 °C. 159 
 160 
Cell culture 161 
 162 
The U-937 cell line (American Type Culture Collection, Rockville, MD) was cultured at 37 °C in a 163 
humidified atmosphere with 5% CO2 in RPMI 1640 medium, supplemented with 10% FCS and 50 164 
µg/ml gentamicin. Cells in exponential growth were used for all experiments. 165 
Before seeding, viability of U-937 cells was tested by Trypan Blue assay. Cells were used only 166 
when viability was higher than 90%.  167 
 168 
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Cell growth inhibition assays (IC50) 169 
 170 
Exponentially growing U-937 cells were seeded at a density of 10
4
 cells in 100 µl of RPMI 1640 171 
in a 96-well culture plate and incubated under a 5% CO2 atmosphere. These were then exposed to 172 
different concentrations of coumarins, ranging from 0.15 µM to 2.0 mM, or 0.6% (v/v) DMSO 173 
(vehicle control group) and later processed as previously described by Riveiro et al. in order to 174 
determine the IC50 value (Riveiro 2004).  175 
To evaluate the time course of U-937 cell proliferation, the number of cells was determined using 176 
a cell counter Coulter Z-1. Briefly, 10
5
 cells/ml were seeded in 24 wells plates and treated with 177 
different concentrations of the compounds to be tested, 400 µM db-cAMP (positive control), or 0.1% 178 
(v/v) DMSO (vehicle control group) for 3 days. Cells were then collected at different times according 179 
to each experiment, and the number was determined using a Coulter Z-1. 180 
 181 
Measurement of the cytotoxic concentration 50 (CC50)  182 
 183 
Cells growing in exponential phase were seeded at 3.5 x 10
5
 cells in 1 ml of RPMI 1640 in a 48 184 
well culture plate and incubated in a 5% CO2 atmosphere. They were then exposed to different 185 
coumarin concentrations (0.15 μM to 2.0 mM) or 0.6% (v/v) DMSO (vehicle control group) for 48 h, 186 
after which the CC50 values were determined as previously reported by our group (Riveiro, 2004) 187 
 188 
Cell cycle analysis 189 
 190 
U-937 cells growing in exponential phase were treated with different concentrations of toddaculin 191 
(6) or 2% (v/v) DMSO (positive control for apoptosis group) for 24 h or 48 h. Then, cells were 192 
harvested and centrifuged at 1000 rpm for 5 min. Cell suspensions were fixed and permeabilized by 193 
vigorous addition of nine volumes of ice-cold 70% (v/v) ethanol and stored at -20 °C for a minimum 194 
of 24 h, prior to analysis. Cells at a density of approximately 10
6
 were re-suspended in 800 μl of PI 195 
staining solution (20 μg/ml propidium iodide and 200 μg/ml RNase A in PBS, pH 7.4) and incubated 196 
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in the dark at room temperature for 30 min. The percentages of cells in the sub-G0/G1, G0/G1, S 197 
and G2/M cell cycle phases were determined over a range of concentrations and time points, and 198 
data from at least three independent experiments were analyzed using Cyflogic free software 199 
(www.cyflogic.com).  200 
 201 
Clonogenic assay 202 
 203 
U-937 cells were treated with different concentrations of toddaculin (6) or 0.1% (v/v) DMSO 204 
(vehicle control group). After 24 h of incubation, 2.5 x 10
3
 treated and control cells were washed 205 
extensively and resuspended in 1.5 ml of mixture containing 0.4% (w/v) agar select and 15% FCS-206 
RPMI 1640 medium. Each cell suspension was seeded over a bottom layer containing 0.7% (w/v) 207 
agar select and 15% FCS-RPMI 1640 medium in a 6 well culture plate. Plates were incubated in a 208 
5% CO2 atmosphere for 4 weeks. The colonies were stained with crystal violet (0.5% w/v), and 209 
colonies containing at least 50 cells were scored using a stereomicroscope. 210 
 211 
Evaluation of morphological changes 212 
 213 
Cells in exponential growth were seeded at a density of 7.5 x 10
5
 cells in 2 ml of RPMI 1640 in a 214 
24 well culture plate and incubated in a 5% CO2 atmosphere. Cells were exposed to different 215 
concentrations of toddaculin (6; 0.05 mM – 1.0 mM) or 0.1% (v/v) DMSO (vehicle control group). 216 
The morphology of treated and untreated cells was examined after 24 h of incubation by triplicate in 217 
at least three independent experiments, as reported by Riveiro et al., 2008a. 218 
 219 
Western blot assays 220 
 221 
Cells were lysed in 50 mM Tris–HCl pH 6.8, 2% SDS, 100 mM 2-mercaptoethanol, 10% glycerol 222 
and 0.05% bromophenol blue, and sonicated to shear DNA. Total cell lysates were resolved by 223 
SDS-PAGE, and probed with the indicated primary antibodies. In the case of the MAPKs and Akt 224 
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pathways, membranes were first incubated with p-Akt, p-ERK 1/2, p-JNK and p-p38 primary 225 
antibodies, then stripped and re-probed for total Akt, ERK 1/2, JNK and p38 antibodies to verify 226 
equal loading of protein. All blots were incubated with horseradish peroxidase conjugated anti-rabbit 227 
or anti-mouse antibodies and developed by enhanced chemiluminescence (ECL) following the 228 
manufacturer’s instructions (Amersham Life Science, England).  229 
 230 
Caspase-3 activity 231 
 232 
U-937 cells growing in exponential phase (3.5 x 10
5
 cells/ml) were treated with different 233 
concentrations of test compounds, 2% (v/v) DMSO (positive control) or 0.1% (v/v) DMSO (Vehicle 234 
control group) during 24 h or 48 h. After that, cells were harvested and processed according to 235 
CASP3C caspase-3 colorimetric assay kit provided by Sigma Chemical Co. (St. Louis, USA). 236 
 237 
Surface myeloid CD11b and CD14 antigens assay  238 
 239 
U-937 cells (3.5 x 10
5
 cells/ml) were treated with different concentrations of the compounds to 240 
be tested, 0.1% (v/v) DMSO (vehicle control group) or 400 µM db-cAMP (positive control group) for 241 
72 h. Treated and control cells were washed twice in PBS and incubated with a saturating 242 
concentration of phycoerythrin (PE) anti-CD11b or anti-CD14 antibody (BD Pharmingen) at 4 ºC for 243 
30 min. In all cases isotype-matched control monoclonal antibodies were used, and a gate
 
(R1) was 244 
defined in the analysis to exclude all nonviable cells
 
and debris, based on size and propidium iodine 245 
staining. Analysis
 
was performed using a FACS flow cytometer and CellQuest software
 
(BD 246 
Biosciences). The results are expressed as mean fluorescence
 
intensity with respect to control 247 
(non-treated cells).
 
 248 
 249 
250 
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Determination of CD88 expression, NBT reduction capacity and chemotactic response 251 
 252 
U-937 cells (3.5 x 10
5
/ml) were treated with the compounds to be tested, 400 µM db-cAMP or 1 253 
µM ATRA (positive control), or 0.1% (v/v) DMSO (control group) for 72 h. Cells from each 254 
experimental group were processed in order to determine the expression of the C5a complement 255 
factor receptor (CD88), NBT reduction capacity and chemotactic response, according to well-256 
described methods previously reported by our group (Riveiro et al., 2004). 257 
 258 
Statistical analysis 259 
 260 
Statistical analysis was performed by one-way ANOVA followed by the Student–Newman–Keuls 261 
(SNK) a posteriori test using InfoStat software (2009). A p-value of 0.05 or less was considered 262 
statistically significant. In order to satisfy the requirements of the one-way ANOVA test, logarithmic 263 
transformation of data was applied to achieve homoscedasticity of the variable when necessary.  264 
 265 
 266 
Results 267 
 268 
Evaluation of the cytotoxic and anti-proliferative effects of prenylated coumarins isolated from T. 269 
asiatica in U-937 cells 270 
 271 
As depicted in Table 1, toddaculin (6) showed the highest anti-proliferative activity in U-937 cells 272 
among the natural coumarins tested, with an IC50 value of 51.38 ± 4.39 (Table 1, IC50 value for 273 
toddaculin (6) vs. IC50 values for coumarins 1 – 5, p < 0.01). Trypan blue exclusion assay was then 274 
performed to examine the cytotoxic effects of these natural coumarins. Toddaculin (6) was the most 275 
potent inducer of cytotoxicity, with a CC50 value of 138.90 ± 3.50 (Table 1, CC50 value of toddaculin 276 
(6) vs. CC50 values for coumarins 1 – 5, p < 0.01).  277 
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The synthetic compound 5,7-dimethoxy-4-methylcoumarin (7) was also tested in order to 278 
evaluate the influence of the 5,7-dimethoxy substitution pattern in the anti-proliferative and cytotoxic 279 
activities of the coumarins under study herein. As shown in Table 1, 5,7-dimethoxy-4-280 
methylcoumarin (7) exhibited neither growth inhibitory nor cytotoxic activities in U-937 cells after 48 281 
h of treatment, indicating that the activities of coumarins 1, 3, 4, 5 and 6 cannot be attributed to the 282 
methoxyl residues in their structures.  283 
Subsequently, a series of experiments were conducted in order to better characterize the anti-284 
proliferative effects observed for toddaculin (6). Figure 1 shows that the coumarin inhibited cell 285 
proliferation and induced cytotoxicity in U-937 cells in a concentration-dependent manner. Finally, 286 
the survival capability of U-937 cells after toddaculin (6) treatment was evaluated by means of 287 
clonogenic survival assays (Franken, 2006). Significant differences were found between the colony 288 
forming rates of cells subjected to a 24-h treatment with either 100 or 250 µM toddaculin (6) and 289 
control cells (Figure 2), pointing out that toddaculin (6) induces irreversible loss of U-937 cell 290 
viability. 291 
 292 
Toddaculin (6) induces apoptosis in U-937 cells 293 
 294 
A series of assays were perfomed in order to determine whether the decrease in U-937 cell 295 
viability evoked by toddaculin (6) at cytotoxic micromolar concentrations resulted from induction of 296 
apoptosis. Both after 24-h and 48-h (Figure 3.A and B, respectively), toddaculin (6) at 250 µM 297 
significantly increased the percentage of U-937 cells in the sub G0/G1 phase of the cell cycle. Also, 298 
treatment of U-937 cells with 250 µM toddaculin (6) for 24 h induced morphological changes 299 
typically associated with the apoptotic process, such as cell shrinkage, chromatin condensation 300 
(pyknosis) and nuclear segmentation (Figure 3.C). 301 
Apoptotic and necrotic cells were detected by studying chromatin condensation with HO test and 302 
nuclear staining with PI. Figure 3.D shows that apoptosis was the prevailing form of cell death 303 
induced by toddaculin (6) at lower concentrations than 500 µM, whereas necrosis was negligible. 304 
However, when cells were exposed to higher concentrations of toddaculin (6), the percentage of 305 
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necrotic cells increased significantly, suggesting that toddaculin (6) is capable of inducing apoptosis 306 
or necrosis in U-937 cells depending on the concentration.  307 
In subsequent experiments, the effect of toddaculin (6) treatment on the activation of caspase-3, 308 
a key enzyme involved in the programmed cell death process, was evaluated. Toddaculin (6) was 309 
able to induce caspase-3 cleavage in U-937 cells, in a time and concentration dependent manner 310 
(Figure 4.A and B, respectively). Caspase-3-mediated proteolytic cleavage of the 116 kDa Poly 311 
(ADPribose)-polymerase protein (PARP) results in the separation of the N-terminal binding domain 312 
(24 kDa) from its C-terminal catalytic domain (89 kDa). It can be seen in figure 4.C that cleaved 313 
PARP (89 kDa) levels increased significantly after treatment of U-937 cells with toddaculin (6) at 314 
concentrations higher than 100 µM. These results were further confirmed by caspase-3 enzymatic 315 
activity measurements (Figure 4.D), indicating that toddaculin (6)-induced apoptosis in U-937 cells 316 
occurs through activation of caspase-3. Interestingly, none of the remaining natural coumarins 317 
herein evaluated (1 – 5) nor the synthetic one (7) displayed pro-apoptotic activity in the same range 318 
of concentrations as toddaculin (6, data not shown). 319 
 320 
The pro-apoptotic activity of toddaculin (6) in U-937 cells entails down-regulation of p-ERK and 321 
p-Akt but not p-JNK or p-p38.  322 
 323 
The treatment of U-937 cells with toddaculin (6; 250 µM) for up to 24 h had no effect on JNK or 324 
p38 apoptosis-associated signaling pathways (Figure 5.A and B, respectively). Nevertheless, a 325 
short exposure (< 1 h) to 250 µM toddaculin (6) induced p-ERK 1/2 and p-Akt downregulation 326 
(Figures 5.C and D, respectively). Collectively, these findings indicate that the pro-apoptotic activity 327 
of toddaculin (6) in the U-937 cell line implies down-regulation of kinases involved in cell survival, 328 
with no effect on MAPKs stress/apoptosis-related pathways.  329 
 330 
Toddaculin (6) induces partial differentiation in U-937 leukemic cells 331 
 332 
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Figures 6.A, D and E show the inducing effect of a 48-h treatment with 50 µM toddaculin (6) on 333 
CD11b expression, NBT reduction capacity and functional CD88 expression in U-937 cells, 334 
respectively. However, toddaculin (6) induced U-937 cells to undergo partial differentiation since 335 
CD14 up-regulation or enhanced chemotactic response in U-937 cells were not observed in treated 336 
U-937 cells. The rest of the coumarins listed in Table 1 were unable to induce the expression of the 337 
differentiation markers herein evaluated in U-937 cells (data not shown). Furthermore, Figure 7 338 
shows that the partial differentiating activity of toddaculin (6) in U-937 cells did not involve 339 
modulation of MAPKs or Akt signaling pathways (Figure 7.A, B, C and D, respectively).  340 
 341 
 342 
Discussion 343 
 344 
In an effort to offer novel compounds with well-established structure for the development of new 345 
chemotherapeutic agents, over the last years we have focused our research predominantly on 346 
coumarins. In the present work, we found toddaculin (6) to be the lead molecule among a series of 347 
natural prenylated coumarins isolated from Toddalia asiatica, owing to its highest capacity to induce 348 
anti-proliferative and cytotoxic effects in a concentration-dependent manner. Importantly, these 349 
effects remained after exposure to the coumarin, restricting the capacity of U-937 cells to form 350 
colonies in soft agar. Further studies revealed the involvement of caspase-3 activation in the pro-351 
apoptotic activity of toddaculin in (6) U-937 cells, suggesting it may serve as a starting structure for 352 
the development of potential cytotoxic anti-leukemic agents.  353 
The pro-apoptotic activity of toddaculin (6) involved a rapid down regulation of both p-Akt and p-354 
ERK 1/2 levels. The Ras/Raf/MEK/ERK pathway is over-expressed in different cancer types and it 355 
has been proposed that this might influence resistance of some cancers to chemotherapeutic 356 
agents (McCubrey, 2007. Ozaki, 2010). The serine/threonine kinase Akt is the most studied effector 357 
of the phosphoinositide 3-kinase (PI3K). Emerging studies have revealed a key role of the PI3K/Akt 358 
pathway in carcinogenesis and chemoresistance in several tumor cells (Falasca, 2010. Martelli, 359 
2006. Yuan, 2003). In the particular case of acute myeloid leukemia, several authors have pointed 360 
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out the existence of a correlation between elevated PI3K/Akt signaling and poor prognosis of these 361 
patients (Gallay and Kornblau, 2009). The cited chemoresistance has been linked to the fact that 362 
the PI3K/Akt pathway controls the expression of the multidrug resistance-associated protein 1 363 
(MDR1), which mediates the extrusion of several chemotherapeutic drugs from leukemic cells and 364 
is associated with a lower survival rate (Schaich, 2005. Tazzari, 2007). Hence, the down-regulation 365 
of both the Ras/Raf/MEK/ERK and PI3K/Akt pathways is nowadays considered an important 366 
strategy for the treatment of cancer (Falasca, 2010. Martelli, 2006. Yuan, 2003). In this regard, 367 
toddaculin (6) makes an attractive lead compound for further development of promising anti-368 
leukemic agents.  369 
Another reason why toddaculin (6) should be viewed as an interesting compound for novel anti-370 
leukemic drug design is that it induces apoptosis in a p53-independent manner, this argument is 371 
based on the fact that U-937 cells are p53-defficient. Often, cancer cells develop resistance to a 372 
given chemotherapeutic agent when it exerts pro-apoptotic effects through the p53 pathway. Thus, 373 
the development of new drugs which act in a p53-independent form would constitute a novel 374 
therapeutic strategy for overcoming multidrug-resistance in leukemia. 375 
Our group and others have described the differentiating activity of certain coumarins in different 376 
malignant cell lines, but none is structurally related to toddaculin (6) (Finn, 2004. Kawaii, 2000. 377 
Riveiro, 2004 and 2009. Zhang, 2003). Likewise, in the literature it is well reported that various 378 
cytotoxic agents also trigger leukemic cell differentiation when they are used at low concentrations 379 
(Cai, 2000. Lemarie, 2006. Pérez, 1994). Therefore, the possibility that low concentrations of 380 
toddaculin might induce differentiation in U-937 cells was also evaluated. In this regard, the present 381 
report demonstrates for the first time the capacity of toddaculin (6) to induce both CD11b and 382 
functional C5a receptor (CD88) expression in U-937 cells, as well as the metabolic changes leading 383 
to NBT reduction. In contrast, Toddaculin (6) did not induce CD14 expression or chemotaxis of U-384 
937 cells in response to C5a. Of interest, this differentiating activity of toddaculin (6) did not involve 385 
modulation of ERK 1/2 and Akt phosphorylation levels as the pro-apoptotic effect did. Certainly, 386 
understanding the precise mechanisms of action of toddaculin (6) in U-937 cells represents an 387 
interesting topic for further investigation. Moreover, in accordance with other authors, we are of the 388 
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opinion that compounds with dual pharmacological behavior, such as toddaculin (6), might serve as 389 
a useful criterion for identification and prioritization of candidate compounds with potential 390 
application in the development of novel anti-leukemic drugs (Vizirianakis, 2010).  391 
Our results also provide evidence of a correlation between some structural properties of 392 
toddaculin (6) and its anti-leukemic activities in vitro. Findings obtained for coumarin 7 during the 393 
present research point out that the methoxyl groups at positions 5 and 7 would not be involved in 394 
the pro-apoptotic or differentiating effects of toddaculin (6) in U-937 cells. On the other hand, our 395 
data illustrate the key role of the prenyl residue at position 6 for both activities. Of note, aeculeatin 396 
(1), coumarin 2, toddanol (4) and toddalactone (5) also have a prenyl residue at position 6, and the 397 
substituent at C-6 of coumarin 2 is very similar to that of toddaculin (6). However, the latter was the 398 
unique compound of the series with pro-apoptotic activity. These observations emphasize the direct 399 
relationship between the cited residue and the pharmacological activities of toddaculin (6). Thus, 400 
future structure-activity relationship studies of toddaculin (6) should be based on this portion of the 401 
molecule. 402 
In conclusion, this is the first report describing the dual pharmacological profile of toddacullin (6) 403 
in U-937 cells, as well as the reasons that justify the ongoing study of this molecule in order to move 404 
toward clinical development. Further research will confirm whether toddaculin (6)-induced apoptosis 405 
and partial differentiation represent two different suitable approaches for the management of 406 
leukemia.  407 
 408 
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Figure 1. Concentration and time-dependent decrease of U-937 cells viability due to 526 
toddaculin (6) treatment. U-937 cells in exponential growth were treated with increasing 527 
concentrations of toddaculin (6) (5 µM, 25 µM, 50 µM, 100 µM and 250 µM) or 0.1% (v/v) DMSO 528 
(vehicle control group, not shown), and the effects on cell proliferation (graphic A) and viability 529 
(graphic B) were evaluated at different times (24 h, 48 h and 72 h) employing a Coulter Z-1 cell 530 
counter and performing the trypan blue exclusion assay, respectively. In both graphics, one-way 531 
ANOVA test (p < 0.01) was performed followed by SNK a posteriori test (**p < 0.01; ***p < 0.001). 532 
Significant differences were evaluated respect to vehicle control group (data not shown) at each 533 
time, in order to determine the effect of the treatment concentration on the biological effects. Each 534 
bar and vertical line represents the mean ± SEM (n ≥ 3). 535 
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Figure 2. Irreversible effects of toddaculin (6) on U-937 cells viability. U-937 cells in 554 
exponential growth were exposed to increasing concentrations of toddaculin (6) (5 µM, 25 µM, 50 555 
µM, 100 µM and 250 µM) or 0.1% (v/v) DMSO (vehicle control group). After 24 h of treatment, cells 556 
from each treatment were seeded in soft agar and the number of colonies generated in these 557 
conditions was determined 2 to 3 weeks later. One-way ANOVA test (p < 0.01) was performed 558 
followed by SNK a posteriori test (**p < 0.01 vs. vehicle control group). Each bar and vertical line 559 
represents the mean ± SEM (n = 3). 560 
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Figure 3. Pro-apoptotic effects of toddaculin (6) in U-937 cells. Control cells, 2% (v/v) DMSO-581 
treated cells (pro-apoptotic positive control group) or U-937 cells treated with increasing 582 
concentrations of toddaculin (6) (25 µM, 50 µM, 100 µM and 250 µM) were analyzed in order to 583 
detect cell cycle variations after a 24-h or a 48-h treatment (graphic A and B, respectively). Graphic 584 
C shows the typical morphological changes associated with apoptosis in U-937 cells after a 24-h 585 
treatment with 250 µM toddaculin (6), as visualized by double staining with HO and PI. Arrows 586 
represent condensed chromatin, fragment nuclei and apoptotic bodies. Graphic D shows the 587 
nuclear morphology changes of U-937 cells treated with increasing concentrations of toddaculin (6) 588 
for 24 h. Necrosis was assessed by the staining of nuclei with PI, whereas apoptosis was visualized 589 
by the appropriate changes of nuclei stained with HO. In graphics A, B and D, each bar and vertical 590 
line represents the mean ± SEM (n ≥ 3). In these cases one-way ANOVA test (p < 0.01) was 591 
performed followed by SNK a posteriori test (**p < 0.01; *p < 0.05). In graphic C, each picture is 592 
representative of three independent experiments. 593 
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Figure 4. Toddaculin (6)-mediated caspase-3 activation in U-937 cells. U-937 cells were treated 609 
with different concentrations of toddaculin (6) (50 µM, 100 µM, 250 µM and 500 µM) or 2% DMSO 610 
(positive control of apoptosis) and harvested after 24 h. Equal amounts of protein were subjected to 611 
SDS-PAGE and analyzed by Western blot with an anti-caspase-3 antibody detecting the 612 
procaspase-3 (Pro-C3) and the cleavage fragments (C3 20 kDa, C3 17 kDa and C3 11kDa, 613 
respectively. Graphic A). Graphic B shows the kinetics of caspase-3 activation in U-937 cells, as 614 
detected by Western blot after treatment with 250 µM toddaculin (6). Graphic C shows the 615 
toddaculin (6) concentration-dependent cleavage of PARP in U-937 cells after a 24-h treatment. 616 
The enzymatic activity of caspase-3 was measured in control cells, 0.1% (v/v) DMSO (vehicle 617 
control group), 2% (v/v) DMSO (positive control group) or 50 µM, 100 µM and 250 µM toddaculin 618 
(6)-treated U-937 cells after 24 h (Graphic D). Data in this graphic were log-transformed before 619 
performing a one-way ANOVA test (p < 0.01) followed by SNK a posteriori test (**p < 0.01 vs. 620 
vehicle control group) to evaluate significant variations in caspase-3 activity. Each bar and vertical 621 
line represents the mean ± SEM (n = 3). Pictures A, B and C are representative of at least three 622 
independent experiments. 623 
 624 
 625 
 626 
 627 
 628 
 629 
 630 
 631 
 632 
 633 
 634 
 635 
 636 
24 
 
Figure 5. Toddaculin (6) regulates Akt and ERK 1/2 signaling pathways at pro-apoptotic 637 
concentrations in U-937 cells. Cells in exponential growth were treated with 250 µM toddaculin 638 
(6) and harvested at different times during a period of 24 h. Equal amounts of protein were 639 
subjected to SDS-PAGE and analyzed by Western blot with anti-p-JNK and JNK antibodies (A), 640 
anti-p-p38 and p38 andibodies (B), anti-p-ERK 1/2 and ERK 1/2 antibodies (C) and anti-p-Akt and 641 
Akt antibodies (D). Pictures A – D are representative of at least three independent experiments. 642 
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Figure 6. U-937 cell expression of differentiation markers induced by low concentrations of 664 
toddaculin (6). Expression of CD11b (A) and CD14 (B), chemotactic ability (C), NBT reduction (D) 665 
and intracellular Ca
2+ 
mobilization induced by rhC5a due to CD88 expression (E) were evaluated 666 
after a 48-h (A, D and E) or a 72-h (B and C) treatment of U-937 cells with increasing 667 
concentrations of toddaculin (6) (5 µM, 25 µM, 50 µM) and 0.1% (v/v) DMSO (vehicle control). In 668 
graphis A – D, differentiation markers are expressed as relative to control cells. Logarithmic 669 
transformation of the data before performing one-way ANOVA test (p < 0.01) followed by SNK a 670 
posteriori test (***p < 0.001; **p < 0.01; *p < 0.05) was applied when necessary. Each bar and 671 
vertical line represents the mean ± SEM (n ≥ 3). db-cAMP (400 µM) was employed as positive 672 
control of CD11b and CD14 expression and chemotaxis in response to rhC5a (A, B and C, 673 
respectively), whereas 1 uM ATRA was the positive control of NBT reduction. In graphic E, arrows 674 
indicate the addition of rhC5a (C5a) or ATP, as positive control of intracellular Ca
2+ 
mobilization. 675 
Cells treated with 400 µM db-cAMP served as positive control of CD88 expression. Similar results 676 
were obtained in at least three independent experiments. 677 
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Figure 7. Evaluation of cell signaling pathways in U-937 cells under differentiating 692 
concentrations of toddaculin (6). U-937 cells in exponential growth were treated with 50 µM 693 
Toddaculin (6) and harvested at different times during a period of 72 h. Equal amounts of protein 694 
were subjected to SDS-PAGE and analyzed by Western blot with anti-p-JNK and JNK antibodies 695 
(A), anti-p-p38 and p38 andibodies (B), anti-p-ERK 1/2 and ERK 1/2 antibodies (C) and anti-p-Akt 696 
and Akt antibodies (D). Pictures A – D are representative of three independent experiments. 697 
